JP7736275B2 - 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 - Google Patents

抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Info

Publication number
JP7736275B2
JP7736275B2 JP2022538731A JP2022538731A JP7736275B2 JP 7736275 B2 JP7736275 B2 JP 7736275B2 JP 2022538731 A JP2022538731 A JP 2022538731A JP 2022538731 A JP2022538731 A JP 2022538731A JP 7736275 B2 JP7736275 B2 JP 7736275B2
Authority
JP
Japan
Prior art keywords
antibody
compound according
hydrogen
alkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508938A5 (cg-RX-API-DMAC7.html
JP2023508938A (ja
Inventor
シー. バード,ジョン
ハートライン,エリン
エイ. エルガマル,オラ
エル. ジョンソン,マライア
トリダンダパニ,スシーラ
イー. ベネット,チャド
マドフカ ヴィブート,サンディップ
イー. グッドウィン,トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hendrix College
Original Assignee
Hendrix College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hendrix College filed Critical Hendrix College
Publication of JP2023508938A publication Critical patent/JP2023508938A/ja
Publication of JP2023508938A5 publication Critical patent/JP2023508938A5/ja
Priority to JP2025136672A priority Critical patent/JP2025186252A/ja
Application granted granted Critical
Publication of JP7736275B2 publication Critical patent/JP7736275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022538731A 2019-12-26 2020-12-26 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物 Active JP7736275B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136672A JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953860P 2019-12-26 2019-12-26
US62/953,860 2019-12-26
PCT/US2020/067074 WO2021134045A1 (en) 2019-12-26 2020-12-26 Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136672A Division JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2023508938A JP2023508938A (ja) 2023-03-06
JP2023508938A5 JP2023508938A5 (cg-RX-API-DMAC7.html) 2024-01-25
JP7736275B2 true JP7736275B2 (ja) 2025-09-09

Family

ID=76575158

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538731A Active JP7736275B2 (ja) 2019-12-26 2020-12-26 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
JP2025136672A Pending JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136672A Pending JP2025186252A (ja) 2019-12-26 2025-08-20 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物

Country Status (7)

Country Link
US (1) US20230303710A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081219A4 (cg-RX-API-DMAC7.html)
JP (2) JP7736275B2 (cg-RX-API-DMAC7.html)
CN (1) CN115335052A (cg-RX-API-DMAC7.html)
AU (1) AU2020412805A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165475A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021134045A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4081215B1 (en) * 2019-12-26 2026-05-20 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
WO2023278778A1 (en) * 2021-06-30 2023-01-05 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
EP4436579A4 (en) * 2021-11-22 2025-10-22 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM IN CONJUNCTION WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIA ACTIONS
WO2025202415A1 (en) * 2024-03-28 2025-10-02 Institut National de la Santé et de la Recherche Médicale Dhodh inhibitors for use in the chronopharmacoligical treatment and prevention of obesity and obesity-related metabolic disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533977A (ja) 2005-03-23 2008-08-28 ゲンマブ エー/エス 多発性骨髄腫の治療のためのcd38に対する抗体
WO2019027973A1 (en) 2017-07-31 2019-02-07 Actinium Pharmaceuticals Inc. TREATMENTS FOR HEMATOLOGICAL MALIGNANCY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
JP6055404B2 (ja) * 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
EP3344243B1 (en) * 2015-09-01 2020-12-09 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
MX2018008169A (es) * 2015-12-30 2019-02-20 Agios Pharmaceuticals Inc Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
US10478497B2 (en) * 2016-07-20 2019-11-19 Hybrigenics S.A. Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
CA3103557A1 (en) * 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
EP4081215B1 (en) * 2019-12-26 2026-05-20 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
EP4081520A1 (en) * 2019-12-26 2022-11-02 Ohio State Innovation Foundation Compositions for use in the inhibition of dihydroorotate dehydrogenase
EP4081512A1 (en) * 2019-12-26 2022-11-02 Ohio State Innovation Foundation Compositions for use for the inhibition of dihydroorotate dehydrogenase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008533977A (ja) 2005-03-23 2008-08-28 ゲンマブ エー/エス 多発性骨髄腫の治療のためのcd38に対する抗体
WO2019027973A1 (en) 2017-07-31 2019-02-07 Actinium Pharmaceuticals Inc. TREATMENTS FOR HEMATOLOGICAL MALIGNANCY

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Diabetes,2013年,62,1084-1093
International Journal of Pharmacy and Pharmaceutical Sciences,2014年,6, Suppl 2,901-903
PLoS ONE,2013年,8(6),e67171, pp.1-10
Scientific Reports,2022年,12,19037, pp.1-30

Also Published As

Publication number Publication date
CN115335052A (zh) 2022-11-11
KR20220133198A (ko) 2022-10-04
CA3165475A1 (en) 2021-07-01
JP2025186252A (ja) 2025-12-23
EP4081219A4 (en) 2024-01-17
JP2023508938A (ja) 2023-03-06
US20230303710A1 (en) 2023-09-28
AU2020412805A1 (en) 2022-07-14
EP4081219A1 (en) 2022-11-02
WO2021134045A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
JP2025186252A (ja) 抗cd38治療剤と組み合わせたジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
US20240294477A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
CA3103674A1 (en) 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2017058771A1 (en) Antibodies that bind human cannabinoid 1 (cb1) recetor
US20240325373A1 (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpa therapeutic agent
JP7800865B2 (ja) ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
US20230089524A1 (en) Compositions for use in the inhibition of dihydroorotate dehydrogenase
HK40082914A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
US20230109418A1 (en) Compositions for use for the inhibition of dihydroorotate dehydrogenase
HK40113342A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent
HK40084674A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40043086A (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40043086B (en) Methods and compositions for inhibition of dihydroorotate dehydrogenase
HK40040411A (en) Therapeutic combinations of a cd19 inhibitor and a btk inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250715

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250722

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250820

R150 Certificate of patent or registration of utility model

Ref document number: 7736275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150